Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Cut by Fiera Capital Corp

Fiera Capital Corp reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 499,109 shares of the company's stock after selling 17,692 shares during the quarter. Fiera Capital Corp owned approximately 0.49% of Neurocrine Biosciences worth $68,128,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp increased its stake in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock valued at $593,186,000 after buying an additional 539,936 shares during the period. Geode Capital Management LLC boosted its holdings in Neurocrine Biosciences by 2.2% in the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company's stock worth $213,773,000 after acquiring an additional 39,610 shares in the last quarter. Braidwell LP raised its stake in shares of Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company's stock worth $105,734,000 after purchasing an additional 158,665 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Neurocrine Biosciences by 145.1% in the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company's stock worth $112,025,000 after purchasing an additional 485,894 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Neurocrine Biosciences by 4.7% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company's stock worth $94,478,000 after purchasing an additional 37,098 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at $338,445. This represents a 30.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the sale, the director now owns 514,596 shares in the company, valued at approximately $76,911,518.16. This trade represents a 22.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 236,600 shares of company stock valued at $34,348,261. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences Trading Down 1.6 %

NBIX stock traded down $1.85 during mid-day trading on Friday, reaching $115.02. The company's stock had a trading volume of 1,479,784 shares, compared to its average volume of 952,604. The stock has a market cap of $11.65 billion, a PE ratio of 34.96 and a beta of 0.33. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The company's 50 day moving average is $137.83 and its two-hundred day moving average is $130.54.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on NBIX. StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Monday, February 10th. UBS Group raised their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a report on Thursday, January 30th. Morgan Stanley lifted their price objective on Neurocrine Biosciences from $170.00 to $185.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Deutsche Bank Aktiengesellschaft initiated coverage on Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a "hold" rating and a $138.00 price target for the company. Finally, Wedbush decreased their price objective on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $166.90.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.